West Q1 sales $698M (+0.4%), adj. EPS $1.45; raises FY2025 net sales and adj. EPS guidance

WEST PHARMACEUTICAL SERVICES INC

2025-Q1 EPS reported $1.23 revenue$698,000,000

Net sales $698.0M (+0.4% reported, +2.1% organic); reported EPS $1.23 vs $1.55 YoY; adj. EPS $1.45 vs $1.56 YoY.
Full-year 2025 net sales guidance raised to $2.945B-$2.975B (prior $2.875B-$2.905B); adj. EPS guidance raised to $6.15-$6.35 (prior $6.00-$6.20).
Q3 2025 dividend declared at $0.21/share, payable Aug 6, 2025 to holders of record July 30, 2025.
Free cash flow $58.1M (up from $27.6M YoY); repurchased 550,281 shares for $133.5M in Q1.
Guidance includes $20-25M net impact from tariffs; organic net sales growth expected ~2%-3% for FY2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.